… for therapeutic use; in addition, drugs that directly or indirectly induce AMPK activation have
potential benefit in prostate cancer … pathways in PCa and discuss related targeted therapies. …

… This is reflected in the vast array of diverse targeted agents that are … prostate cancer ‘lethal
phenotype’, and review the clinical activity of some of the newly approved targeted therapies …

… deprivation therapy (ADT) is foundational in the management of advanced prostate cancer
(… These include approval of new therapies that suppress testosterone (T) levels or inactivate …

… -resistant prostate cancer (mCRPC) is changing due to the emergence of new targeted
therapies … various different novel strategies to improve outcomes in patients with prostate cancer. …

… role in prostate cancer has stimulated the investigation of targeted therapies, including
antiangiogenic agents, bone-targeted … For the most part, targeted agents are being combined with …

… receptor targeting therapeutics for the treatment of advanced-stage prostate cancer over the
… and to discuss the upcoming future and challenges in the treatment of this common cancer. …

… PSMA has been proven to be an excellent target of prostate cancer, because it is (i) primarily
expressed in the prostate, (ii) abundantly expressed as protein at all stages of the disease, (…

… traditional therapies. Great progresses have been made in PCa treatment based on prostate…
The focus of this review is to provide a detailed summary of PSMA-targeted therapies (Fig. 1)…

… of the molecular mechanisms of cancer, we have witnessed unprecedented progress in
developing new forms of targeted therapy. Several targeted therapeutic agents have been …

… In order to develop similar targeted therapies for prostate cancer, critical key molecules
and signaling pathways need to be identified and the effects of inhibition investigated. …